Clinical trials: First Line Treatment
Lymphoma
Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma
RATIONALE: Drugs used in chemotherapy, such as chlorambucil and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00608374
- Testing
- chlorambucil, fludarabine phosphate, quality-of-life assessment
- Where
- 49 sites in Australia, United Kingdom
- Volunteers
- 400 people
- Sponsor
- Taunton and Somerset Hospital
Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma
Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study
The RADIANCE trial plans to enroll patients with chemotherapy-ineligible de novo metastatic nasopharyngeal carcinoma (AJCC 9th edition, TxNxM1).
- Trial name
- RADIANCE (NCT07756190)
- Testing
- Sintilimab, ipilimumab, Radscopal Radiotherapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
TNBC - Triple-Negative Breast Cancer
Talazoparib Maintenance Therapy in Triple-negative Breast Cancer
The investigators propose a randomized phase II clinical trial of talazoparib maintenance therapy in TNBC patients whose tumor showed clinical benefit (platinum-sensitivity) to first- or second-line platinum-based chemotherapy…
- Trial name
- NCT04755868
- Testing
- Talazoparib
- Where
- South Korea
- Volunteers
- 206 people
- Sponsor
- Yonsei University
Multiple Myeloma
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma
The purpose of this research study is to test the safety and effectiveness of replacing vincristine with a drug called bortezomib (also known as "Velcade"or PS341) in the standard therapy vincristine, doxorubicin (not limited to…
- Trial name
- NCT00441168
- Testing
- adriamycin, bortezomib, dexamethasone
- Where
- 16 sites in Croatia, Germany and 5 more
- Volunteers
- 30 people
- Sponsor
- Janssen-Cilag International NV
Non-small Cell Lung Cancer
A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer
To evaluate the safety and tolerability of carbognilumab combined with chemotherapy as the first-line treatment for patients with STK11 mutated advanced or postoperative recurrent non-small cell lung cancer (NSCLC).
- Trial name
- NCT06331650
- Testing
- cadonilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Immune Checkpoint Therapy, Radiotherapy
Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC)
For patients with unresectable locally advanced or metastatic gastric cancer, systemic anti-tumor therapy remains the mainstay of treatment.
- Conditions
- Immune Checkpoint Therapy, Radiotherapy, Metastatic Gastric Carcinoma
- Trial name
- NCT06980389
- Testing
- Node-Sparing Radiotherapy plus first-line therapy, First-line treatment
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Gastric Cancer
Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma
It is a trial to compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus S-1 (SOX) as first-line treatment in advanced or recurrent gastric adenocarcinoma.
- Trial name
- NCT03801668
- Testing
- Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Huazhong University of Science and Technology
Breast Neoplasms, Neoplasms, Hormone-Dependent
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the…
- Trial name
- NCT00267553
- Testing
- Atamestane, toremifene, letrozole
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- Intarcia Therapeutics
Nasopharyngeal Neoplasms
Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
This study is a phase II clinical study. Recurrence after radiotherapy patients who are failure of radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC) were treated by cisplatin and 5-fluorouracil with Sorafenib…
- Trial name
- NCT00747799
- Testing
- Sorafenib plus Cisplatin and 5-fluorouracil
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Lung Adenocarcinoma
Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial
The purpose of this study is to compare chemotherapy and gefitinib in combination with gefitinib alone as first-line therapy for adenocarcinoma, in terms of efficacy and safety.
- Trial name
- NCT02951637
- Testing
- Pemetrexed plus carboplatin combined with gefitinib, Gefitinib
- Volunteers
- 300 people
- Sponsor
- Shanghai Chest Hospital
Ovarian Cancer
Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer
The purpose of this clinical trial is to assess the safety and efficacy of ubamatamab in combination with first-line chemotherapy in patients with ovarian cancer.
- Trial name
- RegeNovar (NCT07637851)
- Testing
- Ubamatamab, Chemotherapy, Bevacizumab
- Where
- 11 sites in France
- Volunteers
- 43 people
- Sponsor
- ARCAGY/ GINECO GROUP
Chemotherapeutic Agent Toxicity, Fatigue
First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chemotherapeutic Agent Toxicity, Fatigue, Lung Cancer, Musculoskeletal Complications
- Trial name
- NCT01097317
- Testing
- carboplatin, vinorelbine tartrate, neuromuscular electrical stimulation
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- Wales Cancer Trials Unit
Lymphoma
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
The purpose of this study is to determine the efficacy and safety of CD19/CD22 Chimeric Antigen Receptor (CAR) T-Cell immunotherapy as first-line consolidation therapy in patients with follicular lymphoma.
- Trial name
- NCT07587840
- Testing
- CD22/CD19 CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Liping Dou
Metastatic Colorectal Cancer
Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment
Investigators propose to study the combination of m FOLFIRI plus Aflibercept in a Phase II trial of patients with metastatic colorectal cancer.
- Trial name
- MINOAS (NCT02624726)
- Testing
- 5 Fluorouracil, Leucovorin, Irinotecan
- Where
- 10 sites in Greece
- Volunteers
- 31 people
- Sponsor
- Hellenic Oncology Research Group
Esophageal Neoplasms
Anlotinib Retrospective Study for Esophageal Cancer
The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal…
- Trial name
- NCT05303740
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Feng Wang
C04.588.274.476.411.307
XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer
XELOX (Capecitabine and Oxaliplatin) is an effective and convenient regimen for patients with metastatic colorectal cancer. Chronomodulated therapy may reduce toxicity.
- Trial name
- NCT00212615
- Testing
- Oxaliplatin (Eloxatin), Capecitabine (Xeloda)
- Where
- 8 sites in Denmark, Sweden
- Volunteers
- 116 people
- Sponsor
- Odense University Hospital
Ovarian Cancer
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer
This Phase 3 study will be conducted in different countries around the world with up to approximately 602 participants. The purpose of this study is to evaluate how well Rina-S alone or in combination with an approved, standard…
- Trial name
- RAINFOL™-10 (NCT07859215)
- Testing
- Rina-S, Bevacizumab
- Volunteers
- 602 people
- Sponsor
- Genmab
HER2 + Breast Cancer
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer
- Trial name
- NCT07294508
- Testing
- HLX87 + HLX22, HLX87 + Pertuzumab, T-Dxd + Pertuzumab
- Where
- China
- Volunteers
- 706 people
- Sponsor
- Shanghai Henlius Biotech
ESCC
Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（ChinECR）
This trial aims to assess efficacy and safety of immunotherapy combined with chemoradiotherapy for first-line treatment of esophageal squamous cell carcinoma.
- Trial name
- NCT06478355
- Testing
- Immunotherapy, Chemotherapy drug, radiotherapy
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Hebei Medical University Fourth Hospital
Colorectal Cancer
Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer
The purpose of this study is to assess the efficacy and safety of Cadonilimab (AK104) combined with chemotherapy and bevacizumab as first-line treatment for patients with RAS mutated or right sided-metastatic MSS colorectal cancer
- Trial name
- NCT06566755
- Testing
- Cadonilimab (AK104) combined with chemotherapy and bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Caigang Liu
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.